Severity
Moderate
FDA Drug recall · Reported September 5, 2018
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Avkare Inc. recalled Valsartan Tablets, USP 80 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-784-15 Manufac… - a moderate-severity action.
Valsartan Tablets, USP 80 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-784-15 Manufac… was recalled by Avkare Inc. in September 5, 2018. Reason: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.. Check the official notice for the remedy. Verify recall #D-1131-2018 with the FDA Drug before acting.
The recall
Avkare Inc. issued this moderate-severity FDA Drug recall-CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product..
Sourced from official FDA Drug enforcement records. Verify recall #D-1131-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1131-2018) was formally reported on September 5, 2018, with the manufacturer initiating the action on August 14, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Avkare Inc. is listed as the recalling firm, operating out of Pulaski, TN. Federal records list the affected scope as 728 cartons (36,400 tablets).
The documented reason for this recall is: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. Distribution data in the federal record shows the product reached: U.S. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
728 cartons (36,400 tablets)
Related Recalls
6
5 from same agency
Valsartan Tablets, USP 80 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-784-15 Manufactured for: AvKARE, Inc. Pulaski, TN 38478
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1131-2018 |
| Date reported | September 5, 2018 |
| Date initiated | August 14, 2018 |
| Recalling firm | Avkare Inc. |
| Firm location | Pulaski, TN |
| Affected scope | 728 cartons (36,400 tablets) |
| Distribution | U.S. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 5, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.